Replies to post #43860 on Curative Biotechnology Inc (CUBT)

[Gonzal]

https://www.acrobiosystems.com/L-1666-CD56.html?gad_source=1&gclid=EAIaIQobChMIibSKjb-whAMVczrUAR3DbA-BEAAYASAAEgJGWfD_BwE

Name Research Code Research Phase Company Indications Clinical Trials

Lorvotuzumab mertansine BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 Phase 2 Clinical Immunogen Inc Ovarian Neoplasms; Leukemia; Rhabdomyosarcoma; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Wilms Tumor; Multiple Myeloma; Sarcoma, Synovial; Neurofibrosarcoma; Neuroblastoma; Carcinoma, Small Cell

Details

GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR GD2/CD56 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms

Details

CUBT-906 CUBT-906 Phase 2 Clinical Curative Biotechnology Inc